Sugi Predict

Sugi Predict / Compounds / SCHEMBL3625005

SCHEMBL3625005

SCHEMBL3625005

c1ccc(CNCc2cccs2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.71
▸ MEN1 O00255 2/20 0.69
▸ KMT2A Q03164 2/20 0.69
▸ L3MBTL1 Q9Y468 2/20 0.61
▸ TDP1 Q9NUW8 2/20 0.61
▸ ALDH1A1 P00352 2/20 0.59
▸ HDAC8 Q9BY41 1/20 0.59
▸ HDAC6 Q9UBN7 1/20 0.59
▸ MAPK1 P28482 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ GFER P55789 1/20 0.59
▸ HPGD P15428 3/20 0.56
▸ RAB9A P51151 2/20 0.56
▸ POLB P06746 1/20 0.54
▸ TP53 P04637 1/20 0.53
▸ THRB P10828 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3159042 0.87 LMNA (0.68) LMNAMEN1KMT2AL3MBTL1TDP1
SCHEMBL22305112 0.86 LMNA (0.68) LMNAMEN1KMT2AL3MBTL1TDP1
Hydrochloric Acid SCHEMBL6122085 0.85 KMT2A (0.69) LMNAMEN1KMT2AL3MBTL1TDP1
SCHEMBL7760992 0.85 LMNA (0.62) LMNAMEN1KMT2AL3MBTL1TDP1
SCHEMBL3423751 0.84 TDP1 (0.74) LMNAMEN1KMT2AL3MBTL1TDP1
Hydrochloric Acid SCHEMBL6122966 0.83 KMT2A (0.68) LMNAMEN1KMT2AL3MBTL1TDP1
SCHEMBL22495343 0.83 GAA (0.58) LMNAMEN1KMT2AL3MBTL1TDP1
SCHEMBL6122653 0.83 LMNA (1.00) LMNAMEN1KMT2AL3MBTL1TDP1
SCHEMBL8826749 0.83 LMNA (0.70) LMNAMEN1KMT2AL3MBTL1TDP1
Hydrochloric Acid SCHEMBL6122570 0.82 LMNA (0.97) LMNAMEN1KMT2AL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119350180-A Industrial preparation method and application of high-purity alpha-aminonitrile 哈尔滨理工大学 2025-01-24 — — CN claimed
EP-0933354-A1 CALCIUM RECEPTOR-ACTIVE COMPOUNDS KIRIN BEER KABUSHIKI KAISHA (JP) 1999-08-04 — — EP claimed
CN-119350180-A Industrial preparation method and application of high-purity alpha-aminonitrile 哈尔滨理工大学 2025-01-24 — — CN disclosed
US-12202829-B2 Heterocyclic compound FIMECS, INC. (JP) 2025-01-21 — — US disclosed
US-20230242529-A1 HETEROCYCLIC COMPOUND FIMECS, INC. (JP) 2023-08-03 — — US disclosed
CN-116507326-A Compounds as GLP-1R agonists 拓臻制药公司 2023-07-28 — — CN disclosed
US-11639354-B2 Heterocyclic compound FIMECS, INC. (JP) 2023-05-02 — — US disclosed
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF Université de Montréal (CA) 2016-07-28 — — US disclosed
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF Université de Montréal (CA) 2016-07-28 — — US disclosed
WO-2015042685-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF VALORISATION-RECHERCHE (CA) 2015-04-02 — — WO disclosed
US-7816408-B2 Calcium receptor active compounds NPS PHARMACEUTICALS, INC. (US) 2010-10-19 — — US disclosed
EP-1746112-A1 Polymerisation catalyst system based on monooxime ligands TOTAL PETROCHEMICALS RESEARCH FELUY (BE) 2007-01-24 — — EP disclosed
US-6939895-B2 Calcium receptor-active compounds NPS PHARMACEUTICALS, INC. (US) 2005-09-06 — — US disclosed
US-6750255-B2 SUCH AS (R)-N-(1-(1'-NAPHTHYL)ETHYL)-2-(2',5'-DICHOROPHENYL THIO)ETHYLAMINE; FOR STIMULATION OF SECRETION OF PARATHYROID HORMONE NPS PHARMACEUTICALS, INC. 2004-06-15 — — US disclosed
US-20030176485-A1 Calcium receptor active compounds NPS PHARMACEUTICALS, INC. 2003-09-18 — — US disclosed
US-20030144526-A1 Calcium receptor-active compounds NPS PHARMACEUTICALS, INC. 2003-07-31 — — US disclosed
US-20020107406-A1 Calcium receptor-active compounds NPS PHARMACEUTICALS, INC. (US) 2002-08-08 — — US disclosed
US-6362231-B1 MODULATOR OF PARATHYROID HORMONE; OSTEOPOROSIS NPS PHARMACEUTICALS, INC. 2002-03-26 — — US disclosed
EP-0933354-A1 CALCIUM RECEPTOR-ACTIVE COMPOUNDS KIRIN BEER KABUSHIKI KAISHA (JP) 1999-08-04 — — EP disclosed
EP-0005014-A1 Clavulanic acid derivatives, preparation and compositions BEECHAM GROUP PLC (GB) 1979-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242529-A1 HETEROCYCLIC COMPOUND XIAP, BIRC5, BIRC3 LMNA 1743/4885MEN1 1434/4885KMT2A 3878/4885
US-20030144526-A1 Calcium receptor-active compounds CASR, CALCR, CNR1 LMNA 4615/4885MEN1 3590/4885KMT2A 2797/4885
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF FBL, HNRNPA1, HNRNPUL1 LMNA 705/4885MEN1 2364/4885KMT2A 1075/4885
US-20030176485-A1 Calcium receptor active compounds CASR, CNR1, CALCR LMNA 4704/4885MEN1 3754/4885KMT2A 2794/4885
US-11639354-B2 Heterocyclic compound XIAP, BIRC5, BIRC3 LMNA 1743/4885MEN1 1434/4885KMT2A 3878/4885
US-12202829-B2 Heterocyclic compound XIAP, BIRC5, BIRC3 LMNA 1743/4885MEN1 1434/4885KMT2A 3878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.